MoumitaBarua Canada

Back

Dr. Moumita Barua is a Clinician Scientist and Assistant Professor in the Division of Nephrology at Toronto General Hospital and the Department of Medicine at the University of Toronto, respectively. The starting point of her research is to perform DNA sequencing in adults with glomerular and chronic kidney diseases. These genetic discoveries inform clinically relevant models to better define mechanisms. Ultimately Dr. Barua's goal is to translate research findings to clinical care for the improvement of diagnostics and outcomes in kidney disease.

Institution

Day 1 - Sunday April 14, 2024

Time	Session

9 a.m. 10:30 a.m.	Hands on Big Data Mining for the Nephrologist in 2024 SK1001 HeatherAscani Chairperson United StatesUniversity of Michigan KatherineTuttle Chairperson United StatesUniversity of Washington School of Medicine, Division of Nephrology MatthiasKretzler Chairperson United StatesUniversity of Michigan Looking for Data on Glomerular Diseases: How to Find the Treasures You Are Looking for With a Click of a Mouse VijiNair Speaker United StatesUniversity of Michigan Open Science in an Open Community: Resources of the Kidney Precision Medicine Project for CKD and AKI MatthiasKretzler Speaker United StatesUniversity of Michigan The Future is Now: How to Mine Cells and Neighborhoods of the Kidney in Health and Disease JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University Panel Discussion Hall C1	APOL1 Targeted Therapies: Who to Test and Which Disease to Treat? SK100 Fatiu AbiolaArogundade Chairperson NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine Ethical Aspects of Race-based Genetic Testing AnaIltis Speaker iltisas@wfu.eduUnited StatesWake Forest University Contribution of ApoL1 Risk Genotype to HIVAN SaraladeviNaicker Speaker South AfricaUniversity of the Witwatersrand Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa DwomoaAdu Speaker dwoms@blueyonder.co.ukGhanaUniversity of Ghana Medical School Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials OgoEgbuna Speaker ogo_egbuna@vrtx.comUnited StatesVertex Pharmaceuticals Inc Q and A Hall C2	Precise Phenotyping and Treatment SK01 HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comArgentinaSanatorio Parque SA Deciphering the IGAN Cell Atlas JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University Complement-mediated Kidney Diseases in the Era of Complement Inhibitors MarinaVivarelli Speaker marina.vivarelli@opbg.netItalyLaboratory of Nephrology, Bambino Gesù Children's Hospital CART-T JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio New Targets to Reduce the Burden of Rare Kidney Diseases LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan Q and A Hall C4
3 p.m. 4 p.m.	New Tools to Study Kidney Disease SK02 RafaelMaldonado Chairperson ramaldonado@gmail.comArgentina ReikoInagi Chairperson JapanThe University of Tokyo Graduate School of Medicine Understanding Glomerular Damage: From Spatial Transcriptomics to Chip Technology LauraPerin Speaker LPerin@chla.usc.eduUnited States Spatial Metabolomics of Kidney Disease TonRabelink Speaker a.j.rabelink@lumc.nlNetherlandsLUMC Constructing an Epigenetic Network for Diabetic Nephropathy Sam El-Osta Speaker sam.el-osta@baker.edu.auAustraliaBaker Heart and Diabetes Institute Q and A Hall E

Day 2 - Monday April 15, 2024

Time	Session

12:15 p.m. 1:15 p.m.	Hot Debate: Genetic Testing in CKD: In High-risk Populations Only or in All Patients with CKD? SK04 MartaAdragna Chairperson marta.adragna@gmail.comArgentina MoumitaBarua Chairperson moumita.barua@uhn.caCanada Hot Debate: Genetic Testing in CKD: In High-risk Populations Only or in All Patients with CKD? - All Patients Albertien M.Van Eerde Speaker NetherlandsDepartment of Genetics, UMC Utrecht, The Netherlands Hot Debate: Genetic Testing in CKD: In High-risk Populations Only or in All Patients with CKD? High-risk Populations Only HilaMilo Rasouly Speaker Hila.MiloRasouly@columbia.eduUnited StatesColumbia University Hall A
4:30 p.m. 5:30 p.m.	Designing Smart Clinical Trials SK05 DebbieGipson Chairperson debbie.gipson@nih.govUnited StatesNational Institutes of Health/NIDDK JonathanBarratt Chairperson United KingdomUniversity of Leicester, Leicester, UK Patients Subphenotyping: The Example of Diabetic Kidney Disease John CijiangHe Speaker cijiang.he@mssm.eduUnited StatesIcahn School of Medicine at Mount Sinai Power of AI to Develop Data-driven Early Detection, Diagnosis, and Management of Kidney Disease LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan Targeted Approaches in Clinical Trial Design HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Q and A Hall D

Day 3 - Tuesday April 16, 2024

Time	Session

9 a.m. 10:30 a.m.	Clinical Management of Glomerulonephritis (GN) SK06 Juan ManuelMejia Vilet Chairperson jmmejia@hotmail.comMexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ValeriaAlberton Chairperson vgalberton@gmail.comArgentinaHospital Fernandez/ Hospital El Cruce Updates on IgAN Management HernánTrimarchi Speaker ArgentinaHOSPITAL BRITÁNICO DE BUENOS AIRES Membranous GN Classification and Management PierreRonco Speaker FranceHôpital Tenon MPGN Updates SanjeevSethi Speaker United StatesMayo Clinic Managing Vasculitis RobertaFenoglio Speaker roberta.fenoglio@unito.itItalyOspedale San Giovanni Bosco Q and A Hall A
12:30 p.m. 1:30 p.m.	New Insights into C3 Glomerulonephritis: Focus on Pathogenesis and Potential Therapeutic Targets SK1003 AnujaJava Chairperson United StatesWASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS LizLightstone Chairperson United KingdomImperial College London Complement in Kidney Disease: Overview of the Complement Cascade in Kidney Injury Peter Zipfel Speaker Peter.Zipfel@hki-jena.deGermanyLeibniz Institute for Natural Product Research and Infection Biology C3 Glomerulopathy: New Developments and Therapeutic Targets CarlaNester Speaker carla-nester@uiowa.eduUnited StatesUniversity of Iowa Challenges in Diagnosing C3G SallyJohnson Speaker sallyajohnson73@gmail.comUnited KingdomNational Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom Q and A Hall C1	Rare and Orphan Diseases SK07 AliGharavi Chairperson ag2239@cumc.columbia.eduUnited States RobertaFenoglio Chairperson roberta.fenoglio@unito.itItalyOspedale San Giovanni Bosco VaninaVazquez Chairperson azquezvanina64@gmail.comArgentina Alport Spectrum Disorders (Genetics) MoumitaBarua Speaker moumita.barua@uhn.caCanada Genetics of Nephrotic Syndrome SimoneSanna-Cherchi Speaker ss2517@cumc.columbia.eduUnited StatesColumbia University Lupus Nephritis Transcriptomics Across Time and Space AnaMalvar Speaker avmperrin@yahoo.com.arArgentinaHospotal Fernandez, Organizacion Medica de Investigacion Q and A Hall E

Pre-Congress - Saturday April 13, 2024

Time	Session

9 a.m. 11 a.m.	Annual Review of Nephrology Course: A Review of Key Topics in Nephrology NAR1 MatiasFerrari Chairperson ferrarimatias89@gmail.comArgentinaSAN MitchellRosner Chairperson United StatesUniveristy of Virginia Health MoumitaBarua Chairperson moumita.barua@uhn.caCanada YelenaDrexler Chairperson yrd6@miami.eduUnited StatesUniversity of Miami Miller School of Medicine Changing Paradigms in the Care of Acute Kidney Injury MarliesOstermann Speaker United KingdomKing's College London Update on Electrolyte Disorders MitchellRosner Speaker United StatesUniveristy of Virginia Health How to Incorporate Genetic Testing in Nephrology MoumitaBarua Speaker moumita.barua@uhn.caCanada Glomerular Diseases: Case Presentation MatiasFerrari Speaker ferrarimatias89@gmail.comArgentinaSAN Q and A Hall C4
11:30 a.m. 1:30 p.m.	Annual Review of Nephrology Course: Treatment Updates for Kidney Diseases NAR2 MatiasFerrari Chairperson ferrarimatias89@gmail.comArgentinaSAN MitchellRosner Chairperson United StatesUniveristy of Virginia Health MoumitaBarua Chairperson moumita.barua@uhn.caCanada YelenaDrexler Chairperson yrd6@miami.eduUnited StatesUniversity of Miami Miller School of Medicine Changing Paradigms in the Care of Chronic Kidney Disease: Slowing Progression Magdalena Madero Speaker MexicoChief of Nephrology, Instituto Nacional de Cardiol What ThiagoDe Azevedo Reis Speaker thiagoreisnefro@gmail.comBrazilHospital Sírio-Libanês, São Paulo, Brazil & Fenix Therapeutic Approaches for Polycystic Kidney Disease Roman-UlrichMueller Speaker roman-ulrich.mueller@uk-koeln.deGermanyUniversity of Cologne Glomerular Diseases: Case Presentation MatiasFerrari Speaker ferrarimatias89@gmail.comArgentinaSAN Q and A Hall C4
2:15 p.m. 4:15 p.m.	Annual Review of Nephrology Course: Glomerular Diseases, Transplantation and Hypertension: What NAR3 MatiasFerrari Chairperson ferrarimatias89@gmail.comArgentinaSAN MitchellRosner Chairperson United StatesUniveristy of Virginia Health MoumitaBarua Chairperson moumita.barua@uhn.caCanada YelenaDrexler Chairperson yrd6@miami.eduUnited StatesUniversity of Miami Miller School of Medicine Glomerular Diseases: Update YelenaDrexler Speaker yrd6@miami.eduUnited StatesUniversity of Miami Miller School of Medicine Transplantation 2023 and Beyond ShrutiTapiawala Speaker IndiaGleneagles Hospital Mumbai , Sir HN Reliance Foundation Hospital and Research Center, Mumbai Hypertension and the Kidney GeorgeThomas Speaker thomasg3@ccf.orgUnited StatesASN Glomerular Diseases: Case Presentation MatiasFerrari Speaker ferrarimatias89@gmail.comArgentinaSAN Q and A Hall C4